NxStage Medical, Inc. (NASDAQ:NXTM) has released a statement revealing that it has installed its NxStage System One in 9 of the top ten Nephrology hospitals in the U.S.
The System One is designed to make it easier to deliver healthcare in cases where patients require acute healthcare. It also makes it possible for the healthcare staff to offer the prescribed renal replacement therapy through various means to patients that are at critical stages of their illnesses.
“The System One simplifies care in acute care settings and allows staff to deliver the prescribed renal replacement therapy via a variety of modalities to critically ill patients,” stated NxStage in its announcement.
The System One boasts various features that were designed to simplify patient therapy when patients are at hospitals. Some of the features it offers include zero special electrical or plumbing needs, no waste bags, and a drop-in cartridge that facilitates multiple therapies. It also features the NxView Interface which has a graphical touch screen that displays medical charts and treatment information.
The range of flow rates offered by the System One also makes it possible for hospital staff to individualize treatment depending on the patient’s condition. The system is designed to provide numerous flexible therapy options for dialysis centers and hospitals. The system One also happens to be the very first truly portable hemodialysis system to be cleared by the FDA for home hemodialysis as well as home nocturnal hemodialysis.
The company has also received a lot of praise for achieving impressively small dimensions with the System One with its height at just one foot. This means it extremely portable, making it even more appealing. NxStage also went a step further to make sure that the system does not require any special infrastructure to operate. The System One can also be paired with the company’s PureFlow SL Dialysis Preparation System and this will offer further simplicity to patients thus providing a lot of value.
NxStage stock closed the latest trading session on Thursday at $28.39 aftera 1.28 percent gain compared to the value of the stock during the previous close.
